Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.56 |
| ▸ | ARG1 | P05089 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.38 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 4/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL1983160 | 1.00 | GSR (0.56) | GSRARG1ALDH1A1GRIK1GRIA1 | |
| SCHEMBL7375810 | 0.84 | GSR (0.43) | GSRALDH1A1PLA2G4ACES1 | |
| Serine SCHEMBL359195 | 0.81 | ALDH1A1 (0.44) | ARG1ALDH1A1GRIK1GRIA1GRIA2 | |
| Serine SCHEMBL359193 | 0.81 | ALDH1A1 (0.44) | ARG1ALDH1A1GRIK1GRIA1GRIA2 | |
| Cysteine SCHEMBL357652 | 0.80 | PTGS1 (0.50) | ARG1ALDH1A1GRIK1GRIA1GRIA2 | |
| SCHEMBL28096157 | 0.80 | ALDH1A1 (0.47) | ALDH1A1PLA2G4ACES1 | |
| Cysteine SCHEMBL1986796 | 0.80 | PTGS1 (0.50) | ARG1ALDH1A1GRIK1GRIA1GRIA2 | |
| SCHEMBL7377556 | 0.80 | ALDH1A1 (0.43) | GSRARG1ALDH1A1GRIK1GRIA1 | |
| SCHEMBL358313 | 0.78 | GSR (0.38) | GSRALDH1A1PLA2G4ACES1 | |
| Glycine SCHEMBL359024 | 0.75 | ALDH1A1 (0.52) | ALDH1A1PLA2G4ACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992518-B2 | Molecular vaccines for infectious disease | AGILENT TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3334498-B1 | METHODS OF TREATING VOLUME DEPLETION AND KIDNEY INJURY | UNIV COLUMBIA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11119104-B2 | Methods of treating volume depletion and kidney injury | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-09-14 | — | — | US | disclosed |
| US-10968269-B1 | MHC multimers in borrelia diagnostics and disease | AGILENT TECHNOLOGIES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210047383-A1 | MHC Multimers in Borrelia Diagnostics and Disease | DAKO DENMARK APS (DK) | 2021-02-18 | — | — | US | disclosed |
| US-20200347103-A1 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | AGILENT TECHNOLOGIES INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10611818-B2 | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics | AGILENT TECHNOLOGIES, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190314471-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10369204-B2 | Molecular vaccines for infectious disease | DAKO DENMARK A/S (DK) | 2019-08-06 | — | — | US | disclosed |
| EP-3334498-A1 | METHODS OF TREATING VOLUME DEPLETION AND KIDNEY INJURY | The Trustees of Columbia University in the City of New York (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2003020897-A2 | COMPOSITIONS AND METHODS RELATING TO OVARY SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020934-A1 | COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020899-A2 | COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020953-A2 | COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020900-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020901-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020102610-A1 | Automated identification of peptides | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-08-01 | — | — | US | disclosed |
| US-20020055186-A1 | Detection of peptides | OXFORD GLYCOSCIENCES (UK) LTD. | 2002-05-09 | — | — | US | disclosed |
| WO-2002025287-A2 | DETECTION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002021139-A2 | AUTOMATED IDENTIFICATION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-14 | — | — | WO | disclosed |